MedTrace Logo

Frontal Cognitive Control Functions Before and After Percutaneous Catheter Procedures in Treatment of Atrial Fibrillation

NCT02306460 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2024-04-10

No results posted yet for this study

Summary

Atrial fibrillation is a common arrythmia. It is an independent risk factor for stroke. There for anticoagulation therapy is used for atrial fibrillation patients. Alternatively, left atrial appendix closure can be used, if the risk for bleeding complications is deemed greater than the possible antithrombotic benefit of anticoagulation medication. Up to 70% of ischemic complications can be prevented with anticoagulation therapy, and left atrial appendix closure seems to have comparable results. Also left atrial catherter ablation (LACA) is gaining popularity as a therapeutic intervention for atrial fibrillation.

However, the procedure is associated with 0,5-1% perioperative risk of clinically evident transient ischemic attack (TIA) or stroke. While the incidence of clinically evident ischemic complications remain relatively low, recent data suggest that 13%-20% of patients undergoing LACA are affected by post-operative neurocognitive dysfunction (POCD) 90 days after ablation.

The goal of the study is to improve detection of subtle brain dysfunction after cardiac interventions by employing an experimental executive reaction time (RT) test along with EEG recording in aims to improve objective detection of subtle brain dysfunction assumed to underlie persistent cognitive, somatic, and affective complaints reported by patients who have undergone atrial fibrillation ablation.

Conditions

Sponsors & Collaborators

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Kaisa Hartikainen, MD, Docent · Behavioral Neurology Research Unit

  • Kati Järvelä, MD, PhD · Tampere Heart Hospital

  • Arvi Yli-Hankala, MD, Professor · Tampere University Hospital

  • Jonne Liimatainen, MD · Tampere University Hospital

  • Pekka Raatikainen, MD, Docent · Tampere Heart Hospital

  • Jaakko Inkovaara, MD · Tampere University Hospital

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-09
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306460 on ClinicalTrials.gov